Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

UBS Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Summary by MarketBeat
UBS Group lowered their price target on Neurocrine Biosciences from $231.00 to $214.00 and set a "buy" rating for the company in a report on Tuesday.

1 Articles

MarketBeatMarketBeat
Center

UBS Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

UBS Group lowered their price target on Neurocrine Biosciences from $231.00 to $214.00 and set a "buy" rating for the company in a report on Tuesday.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Tuesday, September 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Diego icon

San Diego

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal